(Adnkronos) - “I tempi di introduzione di farmaci innovativi sono troppo lunghi: passano al vaglio di Ema, Aifa e delle Regioni. Forse quest’ultimo passaggio può essere evitato. Anche per ottimizzare l’essenza del Fondo” per i farmaci innovativi “che, a oggi, non viene utilizzato per il 35%. Vanno poi inclusi anche quelli a innovatività condizionata. Infine, conto sull’emendamento che vuole portare da 6 a 10 anni la durata dei farmaci innovativi”. Lo ha detto Anna Maria Mancuso, presidente Salute Donna Odv e coordinatrice del Gruppo ‘La salute, un bene da difendere, un diritto da promuovere’, in chiusura del convegno sul contributo dell’innovazione per il trattamento del tumore del polmone.
Category
🗞
NewsTranscript
00:00What do you think should be done to improve the quality of medicine?
00:04Maybe we should try to include in the fund
00:11also those innovative conditioned drugs
00:16because they could be a solution for access to new therapies
00:22for patients who are perhaps waiting to have therapies
00:27that are not yet considered innovative
00:30but that are innovative within the fund
00:33but after six years they come out of innovativeness
00:37and therefore cannot be considered innovative anymore.
00:41This amendment provides for the extension of the possibility
00:45within AIFA to consider an innovative drug
00:49within ten years and not six as a limit
00:52what is now considered
00:56so ten years means that if, for example,
00:59a drug that is used and is considered innovative for lung cancer
01:04is discovered maybe in seven years
01:07which can be innovative and can help
01:10and can also be a solution for another type of pathology
01:13here it is innovative because studies on that pathology
01:17have been conducted
01:20and therefore it is a new pathology
01:23and the patient can access it
01:26without having to resort to compassionate therapies
01:33because sometimes this also happens
01:36compassionate therapies are used
01:39precisely because you cannot access certain innovative drugs
01:43for different pathologies than those that have been indicated.
01:46The access times are quite long
01:51just think that they go through three levels
01:55that is EMA, AIFA and the regions
01:59already shortening these levels
02:03because once they are approved by EMA
02:06then by AIFA and we feel safe
02:09because it is still a control in our country
02:12and the regions could perhaps not go back
02:17to the approvals for innovative drugs
02:21since there is already AIFA that does it at the national level.